Meiji Yasuda Life Insurance’s Neurocrine Biosciences NBIX Stock Holding History

Meiji Yasuda Life Insurance’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$728K	Hold	5,528	–	–	0.02%	161
2025 Q4	$784K	Sell	5,528 -78	-1%	-$11.3K	0.02%	150
2025 Q3	$787K	Hold	5,606	–	–	0.02%	149
2025 Q2	$705K	Hold	5,606	–	–	0.02%	160
2025 Q1	$620K	Sell	5,606 -194	-3%	-$24.6K	0.01%	180
2024 Q4	$792K	Hold	5,800	–	–	0.01%	162
2024 Q3	$668K	Hold	5,800	–	–	0.01%	174
2024 Q2	$798K	Buy	5,800 +2,500	+76%	+$343K	0.02%	177
2024 Q1	$455K	Buy	+3,300	New	+$451K	0.01%	222

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meiji Yasuda Life Insurance's NBIX Position: Q1 2026 in Review

Meiji Yasuda Life Insurance held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 5,528 shares worth $728K. The position accounts for 0.02% of the portfolio, ranked #161.

Meiji Yasuda Life Insurance first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $798K in Q2 2024. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Meiji Yasuda Life Insurance held 5,528 shares of Neurocrine Biosciences worth $728K as of Q1 2026.
Meiji Yasuda Life Insurance left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.02% of Meiji Yasuda Life Insurance's portfolio in Q1 2026, its #161 holding.
Meiji Yasuda Life Insurance first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
Meiji Yasuda Life Insurance's Neurocrine Biosciences position peaked at $798K in Q2 2024.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Meiji Yasuda Life Insurance's 13F filing for Q1 2026, filed 12 May 2026.